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Methods
Construct sequencing information
The GLP1 used in all studies was a modified version, unless otherwise mentioned (as in the cAMP in vitro studies): AAHGEGTFTSDVSSYLEEQAAKEFIAWLVKGAG. All ELPs were comprised of (VPGXG) n repeats where 'X' residue composition and 'n' number of repeats are listed in Table 1. 1.2 Iodination of GLP1-ELP An identical procedure to that outlined in the Methods Section 2.6.4 was performed using non-radioactive NaI to iodinate the tyrosine residue of GLP1. After iodination and overnight dialysis in PBS, the concentrations were determined by measuring 280 nm absorbance on a NanoDrop 1000 and successful iodination was confirmed with matrix-assisted laser desorption and ionization mass spectrometry (MALDI-MS) on a trypsin digested sample (SI Figure 1) . For the tryptic digest, samples were diluted to 25 µM in 50 mM ammonium bicarbonate and incubated with 0.2 µg MS grade trypsin (ThermoFisher Scientific) for 4 h at 37°C. Samples were diluted 1:10 in 10 mg/mL 4-hydroxycinnamic acid (HCCA) matrix prior to analysis with a DE-Pro MALDI-MS (Applied Biosystems). The two unmodified peaks, labeled in black, correspond to the expected peaks for digested, unmodified GLP1 (2299.4 and 1006.2 Da). The peaks labeled in red correspond to the 2299 Da peak modified with one and two iodines.
1.3 Calculation of minimum effective concentration A minimum effective concentration for GLP1-ELPs was calculated using information published on how GLP1's insulin-releasing effects are dependent on an intravenous dose in mice. A 0.3 nmol/kg dose leads to peak concentrations of approximately 100 pM 70 . In a separate study, a dose of between 3 and 10 nmol/kg GLP1 led to an abrupt increase in the second-phase of insulin release 69 . Using linear scaling, a 10 nmol/kg dose would reach peak concentrations in circulation of approximately 3.3 nM. By adjusting for the fusion's 12-fold higher EC 50 , we calculated a minimal effective concentration to be roughly 40 nM.
1.4 Preparation and validation of GLP1-ELP opt for non-human primate study 1.4.1 Assessment of purity with SEC-HPLC Purified GLP1-ELP opt was analyzed with SEC-HPLC using 5% acetonitrile (ACN) in PBS isocratic flow as the mobile phase. The pump flow rate was set to 1 mL/m for a 30 m run time. The sample was diluted to 1 mg/mL in mobile phase and 50 µL was injected. A total of three sample injections were performed. A 50 µL mobile phase blank was also analyzed. The samples were detected with a photodiode array SI Figure 1 . MALDI-MS of trypsinized GLP1 after labeling with iodine. Unmodified peaks for digested GLP1 are labeled in black and iodinated peaks are labeled in red.
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(PDA) at 280 nm (SI Figure 2) . The average percent purity for GLP1-ELP opt was 99.67%. The chromatogram showed a small tailing peak of a smaller species off of the main peak for each of the three sample injections. There were no detected peaks in the blank.
1.4.2 Assessment of purity with RP-HPLC RP-HPLC was performed with a 1 mL/m flow rate using the following gradient: 20% ACN in water with 0.1% TFA increasing over a 30 m run time to 50% ACN in water with 0.1% TFA followed by a 100% ACN in 0.1% TFA wash to strip the column of all remaining molecules. Purified GLP1-ELP opt was diluted to 1 mg/mL in mobile phase and 50 µL was injected. A total of three sample injections were performed in addition to a 50 µL mobile phase blank. The samples were detected with a PDA at 280 nm (SI Figure 3) . The average percent purity for GLP1-ELP opt was 89.02%. The chromatogram showed a front shoulder peak off of the main peak for each of the three sample injections. There were no detected peaks in the blank. Figure 3 . RP-HPLC of purified GLP1-ELPopt product. Figure 2 . SEC-HPLC of purified GLP1-ELPopt product.
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Confirmation of the product's mass and sequence
Mass spectrometry was performed using a Micromass Q-Tof API US Quadrupole/Time-Of-Flight mass spectrometer. GLP1-ELP opt was desalted using a Waters MassPREP online desalting cartridge; the eluted sample was introduced into the instrument in 80% ACN in water with 0.1% formic acid. GLP1-ELP opt gave a positive ion electrospray-MS spectrum with a major series of possible multiply-charged ions. When deconvoluted, these data show a major component with a chemical average molecular mass of 67,474.7 Da (SI Figure 4) , which corresponds to the theoretical MW within the range of the instrument's accuracy. The theoretical MW of GLP1-ELP opt is 67,607.6 Da with an N-terminal Met and 67,476.4 with the N-terminal Met cleaved post-translationally.
Prior to sample analysis, GLP1-ELP opt was buffer exchanged into PBS using a Nanosep 10 k Spin Cartridge (Pall). Pulsed liquid-phase N-terminal sequencing was performed using an Applied Biosystems (ABI) 492 automatic protein sequencer. Seven cycles of Edman degradation were carried out with the ABI program; the major amino acids detected in each cycle are presented in SI Table 1 . A major His peak was also seen in residue 1, however, this was attributed to the presence of histidine in the sample buffer. Table 1 . N-terminal residues of GLP1-ELP opt detected by Edman Degradation.
SI
Residue Cycle Number
Major Amino Acid Detected 1 Ala 2 Ala 3 His 4 Gly 5 Glu
Confirming purified product's activity
The day prior to the activity assay, GLP1R expressing Chinese hamster ovary (CHO) cells were plated on a 96-well tissue culture plate and incubated overnight at 37°C, 5% CO 2 . GLP1-ELP opt was incubated overnight with DPP-IV to cleave the Ala-Ala leader, yielding active peptide for receptor binding. Serial dilutions of native GLP1 control and GLP1-ELP opt were prepared in PBS. The cells were rinsed with Krebs-Ringer Bicarbonate Buffer (KRB) and then incubated at RT with 1 mM IBMX in KRB for 10 m to prevent cAMP degradation. The serial dilutions of samples were then added to the plate in duplicate and the plate was incubated at 37°C, 5% CO 2 for 20 m before lysing the cells to release cAMP. These samples and standards were added to the assay plate, followed by anti-cAMP antibody and competing HRPcAMP; the plate was incubated at room temperature for 2 h. The plate was then washed and stoplight red substrate was added to each well and incubated 1 h at room temperature. The plate was read on a SI Figure 4 . Mass spectrometry shows a major peak for the purified GLP1-ELPopt product at 67,474.7 Da.
fluorescence plate reader with 530 nm excitation, 590 nm emission, and a 570 nm cutoff. GLP1-ELP opt was determined to be 20.1 fold less active than GLP1 (SI Figure 5 ) based on the calculated EC 50 values.
GLP1-ELP Fusion Characterization
2.1 Assessing purity with SDS-PAGE After purifying the GLP1-ELP fusions by ITC, we ran SDS-PAGE gel on 4-20% Tris gradient gels (BioRad). To visually assess purity, these gels were negatively stained with 0.5 M CuCl 2 and the protein bands were compared to a standard ladder (Precision Plus Protein Kaleidoscope, Bio-Rad) to verify size.
Hydrodynamic radius comparisons
The light scattering data for the GLP1-ELP series with varying MWs can be plotted alongside other hydrophilic, unstructured polymers, such as PEG and dextrans (SI Figure 7) , which have similar hydrodynamic radii. The smallest fusion tested, GLP1-ELP 20.0 kDa has an R h comparable to albumin. However, this construct had inferior pharmacokinetics. This could be explained by albumin's negative charge, which is believed to reduce its glomerular filtration in the kidneys, whose basement membrane is also negatively charged. In contrast, the ELP is comprised of uncharged residues. Similarly, SI Figure 9a , shows the same pre-treatment and day 1 blood glucose data for mice treated with either PBS or the series of GLP1-ELPs with variable MW. A small, pilot study was also conducted where mice were injected IV (10 nmol/kg at 1 μM) with dilute GLP1-ELP fusions and blood glucose was subsequently monitored. The samples were diluted to a concentration at which the most hydrophobic fusion in the series did not transition at body temperature. IV injection removed the variable of depotcontrolled release and isolated renal filtration. Even in this pilot study (n=1), it is apparent that GLP1-ELP 20.0kDa , which had the worst performance after SC administration, is also cleared from the body the fastest (SI Figure 9b) , likely owing to its free filtration due to its small size.
Dose response
A dose response study using GLP1-ELP opt was conducted to determine the optimal once-weekly dose (SI Figure 10) . Because the fusion's T t , which has been optimized, is dependent on concentration, we kept concentration constant and instead varied injection volume. In our experience, injection volume has a much less significant impact on depot performance than T t . Mice were injected with 87.5-1400 nmol/kg at 200 μM with injection volumes ranging from about 20 to 270 μL. Negative control mice were injected with PBS at volumes equivalent to the 1400 nmol/kg group. Because no further improvement in blood glucose was achieved with the 1400 nmol/kg dose (SI Figure 10a,c) and there was no statistically significant difference in weight change (SI Figure 10b) , we selected 700 nmol/kg as the optimal dose. 
Biodistribution
The ob/ob mice receiving treatment with radiolabeled GLP1-ELP opt were sacrificed on day 10 postinjection. At this time, relevant organs were excised and subjected to gamma counting to look at the fusion's biodistribution after 10 days of controlled release. The highest gamma counts, normalized to the injected dose, were found at the injection site and in the thyroid (SI Figure 11) , which is unsurprising given its role in taking up iodine for hormone production. There was no significant accumulation in other vital organs, including those responsible for drug disposal -the kidneys and liver.
3.4 Blood glucose returning to untreated levels For ob/ob mice treated with a single SC depot injection, blood glucose lowering effects are observed out to 10 d. Beyond 10 d, the mean blood glucose levels rises and is no longer statistically significantly different from the PBS treated control group (SI Figure 12) .
Images from µSPECT-CT
The main body of the manuscript presents registered µSPECT-CT images for a representative animal from each treatment group at time points relevant to the discussion. Below (SI Figure 13) , we present images from all other mice across all time points at which images were collected. S9 SI Figure 13 . Registered and overlain µSPECT-CT images for all animals in the experiment (n=4). Mice received 50 nmol/kg GLP1 (grey), 700 nmol/kg GLP1-ELPsol (red), or 700 nmol/kg GLP1-ELPopt (blue). Once pharmacokinetics confirmed the drug had been cleared, no further images were taken. Consequently, GLP1 was only tracked for 48 h while soluble and depot-forming GLP1-ELP fusions were tracked for 72 h and 240 h, respectively.
3.6 Injection site histology Histology slides for skin from each mouse (SI Figure 14) , injected with PBS, GLP1-ELP opt , or PLGA microspheres (n=3), were analyzed by a certified pathologist who was blinded to the group assignments. Nothing of interest was found in the PBS treated controls. In one GLP1-ELP sample, the pathologist found a focal apparent perifollicular fibrosis, which may have been due to the shaving methods, as well as mild histiocytic infiltrate. In all PLGA microsphere samples, there was evidence of mild to moderate histiocytic infiltrate. In one sample, there was also a spot of follicular fibrosis and a deep dermal/subcutaneous focus of fat necrosis. These histologic changes are consistent with the time frame of 5 days post-injection of foreign material. Because the GLP1-ELP opt samples looked no worse, if not better than PLGA microspheres (which are FDA approved for the delivery of a GLP1R agonist, exenatide), we are not concerned by any histologic findings. 
Long-term In Vivo Studies in Mice
4.1 Blood glucose and HbA1c correlation Over the course of an 8-week treatment regimen involving injections every 7 days in ob/ob mice and every 6 days in DIO mice, %HbA1c values are correlated to blood glucose exposure (AUC) (SI Figure  15 ).
Blood glucose regulation after repeated injections
We can overlay blood glucose data from different weeks through the course of the 8-week treatment. In DIO mice treated every 6 days with GLP1-ELP opt , there is no apparent reduction in efficacy at injections 4 and 5 compared to the first week of treatment (SI Figure 16 ). This provides indirect evidence against significant levels of circulating anti-drug antibodies, which would likely manifest as reduced efficacy with time.
In Vivo Studies in Monkeys
5.1 Immunogenicity Cynomolgous macaques monkeys were injected with GLP1-ELP opt and blood was collected pre-injection as well as post-injection for 30 days. Anti-drug antibodies (ADAs) were measured by binding either GLP1-ELP opt or native GLP1 to a plate and quantifying the amount of bound mouse antibodies in the a b S12 serum at later time points (24 and 30 days) at which time, little to no drug remained in circulation. ADA measurement was done both with and without the addition of soluble, competitive drug or native GLP1 to determine specificity. Control measurements were made using dilutions of monoclonal mouse anti-GLP1 or polyclonal sheep anti-ELP. After measuring antibody binding as relative fluorescent units (RFUs), the data was presented as (1) fold-increase in RFU of day 24 and 30 serum over pre-dose samples (SI Figure  17 a-b) and (2) as % inhibition when assayed with soluble competition (SI Figure 17 c-d ).
Pharmacokinetics
The serum samples were also used to assess pharmacokinetics by two methods: (1) a sandwich ELISA using anti-GLP1 and anti-ELP antibodies, and (2) a bioactivity assay by applying the serum to GLP1R expressing CHO cells and using cAMP production and a standard curve made by diluting drug in predosing serum. Although ADAs were detected, the high correlation of the pharmacokinetics by bioactivity assay to the pharmacokinetics by ELISA (SI Figure 17e) suggests that these ADAs are not neutralizing.
SI Figure 17 . Measuring anti-drug antibodies and bioactivity assay pharmacokinetics in non-human primates. Control antibodies and monkey serum samples at days 24 and 30 were compared to pre-dose samples for binding to drug (blue) and native GLP1 (black) both without (a-b) and with soluble competition by drug or native GLP1 (c-d). C Pharmacokinetics assessed by bioactivity assay (e) correlated well with pharmacokinetics as measured by ELISA (f). Circles, squares, and triangles represent primates 1, 2, and 3, respectively. Data represent mean and SEM. 
